Cancer is one of the major healthcare challenges across the globe. Several anticancer
drugs are available on the market but they either lack specificity or have poor safety, severe …

Alzheimer's disease (AD) is one of the biggest human health threats due to increases in
aging of the global population. Unfortunately, drugs for treating AD have been largely …

Protein posttranslational modifications (PTMs) refer to the breaking or generation of covalent
bonds on the backbones or amino acid side chains of proteins and expand the diversity of …

Cardio-oncology has organically developed as a new discipline within cardiovascular
medicine as a result of the cardiac and vascular adverse sequelae of the major advances in …

Diabetes and cancer are two heterogeneous, multifactorial, severe, and chronic diseases.
Because of their frequency, reciprocal influences–even minor influences–may have a major …

Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl)
inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson's disease dementia or …

Tyrosine kinase inhibitors (TKI) are effective in the targeted treatment of various
malignancies. Imatinib was the first to be introduced into clinical oncology, and it was …

Parkinson's disease is a movement disorder characterized by death of dopaminergic
substantia nigra (SN) neurons and brain accumulation of α-synuclein. The tyrosine kinase …

Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the
second most common neurodegenerative disease after Alzheimer's. Typical …

In an ever-increasing aged world, Alzheimer's disease (AD) represents the first cause of
dementia and one of the first chronic diseases in elderly people. With 55 million people …